Todd Bazemore

Amazon CloudFront Netriplex Route 53 Mimecast Microsoft Office 365 Amazon AWS Oracle Cloud Adobe Marketing Cloud Google Tag Manager Mobile Friendly New Relic Bootstrap Framework Google Analytics Remote

biotechnology life sciences biotechnology: pharmaceutical preparations health care biotechnology research biopharmaceutical clinical-stage ophthalmic therapy mesenchymal stem cells secretome therapy kpi-012 kpi-014 dry eye disease ocular surface diseases retinal diseases persistent corneal epithelial defect limbal stem cell deficiency gene-agnostic treatments fda approval orphan drug designation fast track designation topical therapy intravitreal therapy regenerative healing therapeutic platform biologics cautions & concerns drug development cell-free therapy biologics license application vision preservation regenerative medicine wound healing ocular inflammation protease inhibitors growth factors matrix proteins clinical trials patient enrollment sight-threatening diseases ocular surgery pain commercial strategy investor relations pharmaceutical innovation clinical research biopharmaceutical industry biotechnology partnerships neuroprotective effects retinitis pigmentosa stargardt disease inherited retinal diseases ocular trauma vision restoration clinical pipeline healthcare innovation innovative therapies rare eye diseases mesenchymal stem cell secretome msc-s platform corneal healing ocular surface repair biologics-based treatments unmet medical needs ophthalmology drug delivery technology patient outcomes healthcare sector advanced science therapeutic development patient demographics competitive landscape strategic partnerships research & development transformative therapies health wellness & fitness hospital & health care